Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Acyclovir × Clear all
NCT01833143 2020-08-04

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
17 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02047253 2018-12-19

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

University of Alabama at Birmingham

Phase 2 Completed
28 enrolled 12 charts
GenitourinaryHead & Neck

Salivary Gland Adenoma, Pleomorphic, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡